Which company does ibrutinib/ibrutinib come from?

Ibrutinib/Ibrutinib is developed and produced by the American pharmaceutical company Janssen Pharmaceuticals. Janssen Pharmaceuticals is one of the pharmaceutical divisions of the US company Johnson & Johnson. Ibrutinib is an oral targeted drug that inhibits BTK. It is suitable for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), Waldenström macroglobulinemia (WM), and mantle cell lymphoma (MCL) who have received at least one treatment in the past.

The active substance in ibrutinibibrutinib can fight against cancerous B lymphocytes, which are a type of white blood cell. It does this by blocking an enzyme called Bruton's tyrosine kinase (Btk), which promotes the survival of B lymphocytes and their migration to organs where these cells normally divide. By blocking Btk, ibrutinib reduces B lymphocyte survival and migration, thereby delaying cancer progression.

Ibrutinib is available by prescription only, and treatment should be initiated and supervised by a doctor experienced in the use of cancer drugs. Ibrutinib is available in capsules (140 mg) and tablets (140, 280, 420 and 560 mg). For patients with mantle cell lymphoma, the dose is 560 mg once daily, and for patients with CLL or WM, the usual dose of ibrutinib is 420 mg once daily. Treatment with ibrutinib should be continued as long as the disease improves or remains stable and side effects are tolerated. If a patient is taking other drugs that may interact with ibrutinib or cause serious side effects, the doctor may reduce the dose or interrupt treatment.